Acute tumour lysis syndrome in a dog with B-Cell multicentric lymphoma

2007 ◽  
Vol 85 (5) ◽  
pp. 206-208 ◽  
Author(s):  
ME Mylonakis ◽  
AF Koutinas ◽  
N Papaioannou ◽  
S Lekkas
2021 ◽  
Vol 32 ◽  
pp. S348
Author(s):  
Megumi Kawamoto ◽  
Yoshiyuki Sano ◽  
Yoshitaka Zenke ◽  
Kenji Kawasumi ◽  
Hiroki Izumi ◽  
...  

2021 ◽  
Vol 8 (25) ◽  
pp. 2149-2154
Author(s):  
Alok Ranjan ◽  
Nisha Khanna ◽  
Vivek Ranjan ◽  
Ashwin Kumar

BACKGROUND Rasburicase (recombinant urate oxidase) has been proven to be an effective therapy for prevention of tumour lysis syndrome (TLS). The recommended daily dosing regimen of rasburicase is 0.2 mg/kg/day for 5 days which is expensive and unaffordable to many patients in the developing countries. The purpose of the present study was to evaluate the effect of single 1.5 mg dose rasburicase in the management of tumour lysis syndrome. METHODS This is a follow-up study done at our institute. Fifty (50) patients with tumour lysis syndrome who received rasburicase from August 2015 to January 2020 were enrolled in this study RESULTS Single dose of rasburicase is effective in decreasing serum uric acid level in significant number (N = 41) of patients. Percentage of patients having uric acid less than 7 mg after single dose of rasburicase in 48 hours - 82.9 % (N = 34) while 17 % (N = 7) were found to have uric acid levels of more than 7 mg/dl. The percentage of patients with uric acid levels more than 7 mg/dl reduced from 36.5 % after 24 hours to 17 % after 48 hours. This indicates that the uric acid levels show a declining trend even after 24 hours without giving an additional dose of rasburicase. There was no relationship between uric acid levels at 24 hours and percentage change in creatinine level from baseline to 24 hours (correlation coefficient (r) = -0.047, P = 0.770. Patients who required additional dose (N = 9) had high base line value of uric acid and their high value was maintained over the follow up period of three days. Patients with pre exiting kidney disease and high level of baseline uric acid also needed dialysis (N = 3). CONCLUSIONS In majority of patients, a single 1.5 mg dose of rasburicase is an effective way to reduce raised uric acid in appropriate circumstances. KEYWORDS Single Dose, Recombinant Urate Oxidase, Uric Acid, Leukemia, Tumour Lysis Syndrome, Rasburicase


2013 ◽  
Vol 2013 (apr23 1) ◽  
pp. bcr2013009532-bcr2013009532 ◽  
Author(s):  
M. Camarata ◽  
R. Davies ◽  
S. Copley ◽  
S. Blagden

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Birthe Osorio ◽  
Heidrun Männle ◽  
Karsten Münstedt

2015 ◽  
Vol 173 (3) ◽  
pp. 485-486 ◽  
Author(s):  
Soufia Ayed ◽  
Caroline Bornstain ◽  
François Vincent

Author(s):  
Ioannis Bellos ◽  
Konstantinos Kontzoglou ◽  
Amanda Psyrri ◽  
Vasilios Pergialiotis

Sign in / Sign up

Export Citation Format

Share Document